Nefarious
发表于 2025-3-28 17:27:16
http://reply.papertrans.cn/19/1880/187998/187998_41.png
generic
发表于 2025-3-28 20:54:00
Tumor Necrosis Treatment and Imaging of Solid Tumorsed in our laboratory. Tumor Necrosis Therapy (TNT) represents a radical departure from current methods that employ monoclonal antibodies (MAbs) to bind to tumor-associated cell surface antigens and require the use of different antibodies for each type of tumor. In contrast, TNT is based upon the hyp
服从
发表于 2025-3-29 00:16:41
Targeted Apoptosis: Antibodies Linked to RNA Damaging Agentswhich new drugs can be designed. For small molecule drugs, the focus is on interfering with molecular targets that contribute to deregulated cell growth and signaling pathways, predominantly within the cancer cell. Antigens aberrantly expressed on the cancer cell surface also afford possible valid m
细微差别
发表于 2025-3-29 03:30:24
http://reply.papertrans.cn/19/1880/187998/187998_44.png
Frequency
发表于 2025-3-29 08:06:47
Rüdiger Esser,Elisabeth FeldmarLarge-scale studies with mortality endpoints comparing fibrinolytic therapy with placebo in patients with acute myocardial infarction (AMI) have documented the benefit of timely dissolution of coronary arterial thrombi by intravenous infusion of plasminogen activators (Fig. 1).(1)
残忍
发表于 2025-3-29 13:45:47
http://reply.papertrans.cn/19/1880/187998/187998_46.png
certain
发表于 2025-3-29 18:48:00
Thrombus Targeting of Plasminogen Activators and AnticoagulantsLarge-scale studies with mortality endpoints comparing fibrinolytic therapy with placebo in patients with acute myocardial infarction (AMI) have documented the benefit of timely dissolution of coronary arterial thrombi by intravenous infusion of plasminogen activators (Fig. 1).(1)
Semblance
发表于 2025-3-29 21:34:38
http://reply.papertrans.cn/19/1880/187998/187998_48.png
Flustered
发表于 2025-3-30 02:14:56
http://reply.papertrans.cn/19/1880/187998/187998_49.png
标准
发表于 2025-3-30 05:37:50
The Most Interesting City in Austriaormidable challenges. Drug targeting strategies have to traverse diverse barriers: biological (e.g., associated with drug delivery, subcellular addressing of a drug, metabolization of carriers, etc), technological (e.g., associated with production, dosing, shelf-life of a drug-carrier complexes) and